Table 3 Chemotherapy regimens and response
From: Presentation and management of pulmonary artery sarcoma
Chemotherapy | No. of patients | Best radiological response |
|---|---|---|
Post-operative | ||
- Epirubicin | 1 | No evidence of disease |
| Â | 1 | Stable disease |
- Doxorubicin | 1 | Progressive disease |
- Ifosfamide | 1 | Stable disease |
- Doxorubicin + ifosfamide | 1 | Stable disease |
Palliative (first-line for inoperable and/or metastatic disease) | ||
- Ifosfamide | 1 | Progressive disease |
- Pegylated liposomal doxorubicin hydrochloride (PLDH) | 1 | Partial response |
- Vincristine + ifosfamide + doxorubicin (VID) | 1 | Partial response |
- Paclitaxel | 1 | Not evaluable |
Palliative (second- and subsequent-line) | ||
- Cisplatin + topotecan | 1 | Stable disease |
- Epirubicin | 1 | Progressive disease |
- Ifosfamide | 1 | Progressive disease |
- Ifosfamide + etoposide | 1 | Progressive disease |
- Paclitaxel | 1 | Progressive disease |